article thumbnail

Osivax publishes phase 2a results supporting dual flu vaccine approach

Pharma Times

The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. Robust NP-specific humoral and cell-mediated immune responses were observed in all participants given OVX836, whether alone or with Fluarix Tetra.

article thumbnail

Bharat Biotech acquires licence for GSK’s Shigella vaccine development

Pharmaceutical Technology

The technology utilises outer membrane vesicles (OMVs) to deliver antigens, often eliminating the need for adjuvants while triggering the immune response. Can pharma tariffs “Make America Manufacture Again”?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

EC approves argenx’s efgartigimod alfa for CIDP treatment

Pharmaceutical Technology

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated neuromuscular disorder of the peripheral nervous system. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

This integration will reinforce Juvenescence’s pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors. Can pharma tariffs “Make America Manufacture Again”? Incorporating Ro5’s AI platform into Juvenescence is expected to accelerate the development of AI-enabled treatments.

article thumbnail

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Can pharma tariffs “Make America Manufacture Again”? Credit: luchschenF /Shutterstock.

article thumbnail

J&J seeks FDA approval for icotrokinra to treat psoriasis

Pharmaceutical Technology

July 22, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook PsO is an immune-mediated disease characterised by rapid skin cell proliferation leading to inflamed plaques that can cause discomfort or pain. Credit: design_cam/Shutterstock.com.

article thumbnail

ADA: Vertex closer to weaning type 1 diabetics off insulin

pharmaphorum

Vertex was also developing a version of the therapy called VX-264 in which the cells were encapsulated in a protective device designed to protect them from rejection by the immune system, but that failed to hit the mark in early clinical testing and has been dropped.